Press Releases

AlloSource Announces First Patients Implanted With AlloWrap Amniotic Membrane In Clinical Study For Two-Level Anterior Cervical Discectomy And Fusion Procedures

Centennial, Colo. — February 23, 2021 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced the first patients have been enrolled in its clinical study titled, A Randomized, Controlled Study to Evaluate Effectiveness of AlloWrap® Amniotic Membrane for the Reduction of Post-Operative Soft Tissue Inflammation in Two-Level Anterior Cervical Discectomy and Fusion (ACDF) Procedures. There are an estimated 300,000 ACDF procedures performed annually in the United States.  Despite the overall positive outcomes of these procedures, one potentially costly and painful complication is inflammation of the surrounding tissue, which can cause…

AlloSource’s ProChondrix CR, Cryopreserved Osteochondral Allograft, To Be Featured At The British Patellofemoral Society Meeting

Centennial, Colo. — November 15, 2020 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced its ProChondrix® CR allograft, will be featured in a presentation by Dr. David Argo at the British Patellofemoral Society Meeting, January 18-19, 2021.  During the session titled ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft.  Dr. Argo, with Beacon Orthopaedics and Sports Medicine in Cincinnati, Ohio, will highlight his experience repairing osteochondral defects of the knee with AlloSource’s allograft. A potentially debilitating condition, chondral injuries are a common issue that affect nearly one million people in…

AlloSource Commits Multi-Year Financial Support To Phoenix Society For Burn Survivors

The generous donation will support burn survivor healing through major initiatives surrounding patient and family care, virtual programming and peer support Centennial, Colo. — December 22, 2020 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, today announced a multi-year donation to Phoenix Society for Burn Survivors in memory of the organization’s founder, Alan Breslau, who passed away this year. “We are proud to support Phoenix Society in their mission to empower anyone affected by a burn injury,” said Thomas Cycyota, President and CEO of AlloSource.…

Science Behind AlloSource’s Cryopreserved Cartilage Published In Journal Of Orthopaedic Surgery And Research

Peer review describes the data behind ProChondrix CR’s ability to maintain the functional components of healthy cartilage after two years of cryopreserved storage Centennial, Colo. — December 8, 2020 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, today announced the Journal of Orthopaedic Surgery and Research published the company’s science in an article titled “Cryopreserved, Thin, Laser-Etched Osteochondral Allograft maintains the functional components of articular cartilage after 2 years of storage.” The article describes data supporting that ProChondrix Cryopreserved (CR) Osteochondral Allograft has  several crucial…

AlloSource Receives Gold Level Recognition For Workplace Health Achievement From The American Heart Association Three Years In A Row

Centennial, Colo. — November 24, 2020 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, today announced it received Gold level recognition from the American Heart Association for continuing to promote a workplace culture of health and wellbeing. Of the 776 organizations that completed the index assessment this year, 35% received gold recognition, 29% silver and 25% bronze. The American Heart Association’s Workplace Health Achievement Index looks at organizational best practices and aggregates employee health data to evaluate the overall quality and comprehensiveness of workplace health…

AlloSource Announces First Patients Complete 12-Month Milestone In ProChondrix CR Clinical Study For Cartilage Defects In The Knee

Centennial, Colo. — November 17, 2020 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced its first patients have completed their 12-month follow-up in its five-year study titled, A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee, looking at the long-term outcomes of ProChondrix CR in the knee. A potentially debilitating condition, chondral injuries are a common issue that affect nearly one million people in the United States annually. As the leader in the processing of cartilage tissue for joint repair,…

AlloSource Honors Dr. Ergun Kocak With The Annual Dr. Steven Gitelis Inspiration Award

Centennial, Colo. — August 4, 2020 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, today announced it is awarding Dr. Ergun Kocak with its fourth annual Dr. Steven Gitelis Inspiration Award. The award honors a physician who understands and embraces the use of donated human tissue to help patients heal. “It’s been an honor to work with AlloSource on innovations in reconstructive surgery,” said Dr. Kocak.  “In my experience, allograft tissue is a crucial part of the procedures I perform, and I am proud to…

AlloSource Names Tendon and Ligament Portfolio Under New Brand AlloConnex

Centennial, Colo. — July 23, 2020 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced it is naming its tendon and ligament portfolio under the new brand AlloConnex™. “Over the past 25 years, our offering of tendons and ligaments has grown, and the timing felt right to package this robust product line under a new brand,” said Kevin Whitten, Senior Vice President, Marketing and Sales.  “AlloConnex aligns with AlloSource’s other brands, while conveying the physical connection of tendon and ligament transplantation through the skilled…

Research Shows ProChondrix CR Maintains Consistent, High Cell Viability For Two Years

Proprietary cryopreservation technique of thin, laser-etched osteochondral allografts provides longer shelf-life, expanding access for cartilage treatment Centennial, Colo. — October 7, 2019 — AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced research results showing ProChondrix® CR maintains consistent, high cell viability for two years when stored at -80̊ C. The research found the presence, on average, of 94.97 percent viable cells in ProChondrix CR. This is representative of the osteochondral allograft’s ability to be used as an effective mechanism of repair for articular defects. The data displays viable cells within…

AlloSource Celebrates 25 Years of Doing More With Life

Milestone highlights organization’s growth into one of the largest tissue banks in the U.S. Centennial, Colo. — August 9, 2019 — AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, will be celebrating 25 years of honoring donors and helping patients heal through the gift of tissue donation starting Saturday. Now the third largest bioscience company in Colorado, AlloSource has grown from a local tissue bank to one of the largest in the country, helping surgeons heal patients around the world. “We achieved this milestone through the hard work and dedication of our…